Audited Financial Results for the quarter and year ended 31st March, 2026
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.5 pts more than Nifty Microcap 250 and 8.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kwality Pharmaceuticals reported strong FY26 results with consolidated revenues of ₹503 crore, up 36% YoY from ₹370 crore. Q4 FY26 saw its highest-ever quarterly topline at ₹157.11 crore (35.8% YoY growth). EBITDA margins expanded to 24% from 22%, driven by improved product mix and higher contribution from regulated markets. PAT grew 69% YoY to ₹67.34 crore with margins expanding to 13.4% from 10.8%. The company completed multiple regulatory audits, received credit rating upgrade to BBB+ from B+, and has a robust pipeline including 40+ OSD molecules and 3+ monoclonal antibodies. An exceptional item of ₹82.94 lakhs was recorded due to labour code changes. Operating cash flow turned negative at ₹-1,699.99 lakh due to elevated receivables (208 debtor days) from Middle East geopolitical disruptions, though cash conversion cycle improved from 208 to 170 days. FY27 guidance: ₹650 crore revenue and ₹100 crore PAT.
Strong revenue and profit growth with margin expansion indicates operational strength. However, negative operating cash flow and elevated receivables due to geopolitical delays in Middle East are concerns to monitor. Credit rating upgrade to BBB+ reflects improved financial profile.